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Review bibliographic data and provide an insight
into:
• Pathogenesis of AD
• How stem cells could help to understand the
disease
• Indentifying possible therapeutic targets using
stem cells.
Research in the Pubmed and ScienceDirect databases.
Keyworkds used: “Alzheimer”, “neural stem cell” [AND]
“therapy”, “neurogenesis”, “iPS”
100 articles from 1998-2015 collected. 58 papers included
in the bibliography prioritized by most cited author and by
journals with a high impact factor.
Fig 1. Cortical thickness studies reveal
atrophied regions in AD brains. In yellow are
indicated the thinner brain structures, followed
by color red in significance[1].
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1. INTRODUCTION
4. PATHOGENESIS OF ALZHEIMER’S DISEASE 5. ADULT NEUROGENESIS AND AD
Alzheimer’s disease (AD) is the most common neurodegenerative disease
affecting millions of people in the world. Cognitive impairments such as
progressive memory loss are devastating manifestations from this
disease. Current pharmacological treatment only relieve symptoms
without a long-term cure. As a result, stem cell therapy is an emerging
potential approach to treat AD. Also, recent advances in reprogramming
technology have studied induced pluripotent stem (iPS) cells to model
the disease.
2. AIM 3. MATERIALS & METHODS
Fig 2. Amyloid plaques formed
by amyloid-β (Aβ) peptide in the
cortex of a patient with AD[2].
6. STEM CELL THERAPY FOR AD 
Fig 3. Neurofibrillary tangles in
AD brain[3].
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Fig 4. Active adult
neurogenesis is restricted
into the subventricular zone
(SVZ) of the lateral ventrile,
where new neurons are
generated and migrate
through the rostral
migratory stream (RMS) to
the olfactory bulb, and the
anterior subgranular zone
(SGZ) in the dentate gyrus
of the hippocampus of
mammalian brains[4].
• Amyloid plaques
• Neurofibrillary tangles
• Cerebral amyloid angiopathy
• Glial responses increased
• Neuronal and synaptic loss
 Ventricle and sulci enlargement
 Cortical thinning of temporal pole,
parietal lobe and parts of the frontal
cortex.
GENETICS IN AD
Between 1 to 5% of all cases,
AD is caused by mutations in:
• Amyloid precursor protein
(APP) gene
• Presenilin genes
GERMINAL REGIONS IN ADULT BRAIN
Neurogenesis is 
implicated into 
memory and 
learning. 
Aβ inhibits 
proliferation of 
neural stem cells 
and promotes 
their apoptosis.
Precursor 
amyloid protein 
(APP) acts as an 
autocrine factor 
to stimulate cell 
proliferation.
7. CONCLUSIONS 8. REFERENCES
ACTIVATION OF ENDOGENOUS NEURAL STEM CELL
Allopregnolone (APα)
Activation of endogenous neural precursor cells (NPCs).
Promote survival of newly generated cells
Fluoxetine
Neuronal differentiation
Protective effects of NSCs
Active Aβ vaccination
Decrease Aβ peptide
Increase hippocampal neurogenesis
Passive Aβ vaccination
Restore neurogenesis
Restore maturation of new hippocampal neurons
Fig 7. Patient-specific induced pluripotent stem
(iPS) cells. Derived by co-expression of
transcription factors in cells isolated from a skin
biopsy. iPS cells represent a new tool for modeling
AD in culture, i.e in vitro.5 Adapted from[6].
Differentiation of iPS cell into affected 
cholinergic neurons
Modeling of the patient’s disease
Potential drugs can be screened
Aid in the discovery of novel 
therapeutic compounds
Table 1. Neuroprotective effects that show chemical compounds and factors in neural stem cells:
Improve of learning and memory in transgenic mice experiments, but there is 
no effect on the underlying Aβ or neurofibrillary tangle pathology.
1. The use of stem cell therapy for the treatment of AD is still at preclinical level.
2. There are promising prospects for permanent treatment for AD with stem cell therapy.
3. Using stem cells to deliver therapeutic proteins it seems the most promising approach to treat AD.
4. The advancement in the use of iPS cells leads to model the disease and could solve the enigma of
restoring the memory.
Brain-derived 
neurotrophic factor 
(BDNF)
Increase synaptic plasticity in entorhinal cortex and 
hippocampus.
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USING NSCs TO DELIVER THERAPEUTIC PROTEINS
Studies in animals models have revealed an improve in memory, learning and spatial
recognition. Also, a decrease in Aβ aggregation and neuronal degradation.
Fig 6. Use of NSCs to deliver therapeutic Aβ-targeting proteins by engineering to the brain.
MODELLING AD WITH iPS CELLS
NEURAL STEM CELL TRANSPLANTATION IN AD
Fig 5. 3xTg-AD mice exhibit robust plaques (A and C; green) and tangles (B; red) within the
hippocampus. 1000 000 GFP-NSCs or vehicle control were stereotactically injected. One month later,
learning and memory was tested. (E) Revealed that NSCs-injected 3xTg-AD mice, exhibit significantly
shorter escape latencies[6].
Transplantation improves cholinergic neuron number and memory.
